DitiocarbDitiocarb
MedChemExpress (MCE)
HY-126363
147-84-2
Diethyldithiocarbamic acid
Please store the product under the recommended conditions in the Certificate of Analysis.
Room temperature in continental US
may vary elsewhere.
Ditiocarb (Diethyldithiocarbamic acid) is an accelerator of the rate of copper cementation. Ditiocarb (Diethyldithiocarbamic acid) reduces the incidence of HIV infection, and also enhances adjuvant immunoresearch of high risk breast cancer.
Ditiocarb reacts with the Cu2+ solution giving a complex of copper diethyldithiocarbamate, which enhances the rate of cementation[1]. Ditiocarb is an agent with strong antioxidant capacity and chelating activities[2].
Ditiocarb improves the depressed immune responses of newborn and aged mice. Ditiocarb prevents cisplatin nephrotoxicity in animals without reducing the antitumor activity. In that AIDS model, Ditiocarb reduces lymphadenopathy and hypergammaglobulinemia, restores immunocompetence, and prolongs survival[2].
| | | |
| | | | | |
[1]. Abeer A.El-Saharty, et al. Sodium diethyldithiocarbamate as accelerator of the rate of copper cementation. The Egyptian Journal of Aquatic Research. 2015 Dec, Volume 41(4):289-293.
[2]. Hersh EM, et al. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA. 1991 Mar 27
265(12):1538-44. [Content Brief]
[3]. Dufour P, et al. Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy. 1993
6(1):9-12. [Content Brief]